期刊
ACS NANO
卷 12, 期 2, 页码 912-931出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.7b05876
关键词
nanotechnology; cancer therapy; oncology; metastasis; biological barriers; drug delivery; gene therapy; immunotherapy; biomaterials; tumor targeting
类别
资金
- Fulbright Canada Killam Fellowship
- Cancer Center Support (core) from the National Cancer Institute [P30-CA14051]
- Burroughs Wellcome Fund Career Award at the Scientific Interface
- National Institutes of Health (NIH)
- Leslie Misrock Cancer Nanotechnology Postdoctoral Fellowship
- Koch Institute for Integrative Cancer Research at MIT
- Koch Institute's Marble Center for Cancer Nanomedicine
- Fundacao Estudar
- Burroughs Wellcome Fund [1015145]
- National Cancer Institute
- Max Planck Society
- National Institutes of Health (NIH) [F32CA200351]
- Dana-Farber/Harvard Cancer Center
- NATIONAL CANCER INSTITUTE [P30CA014051, F32CA200351] Funding Source: NIH RePORTER
The immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has received significant attention as a cancer therapeutic due to its ability to selectively trigger cancer cell apoptosis without causing toxicity in vivo. While TRAIL has demonstrated significant promise in preclinical studies in mice as a cancer therapeutic, challenges including poor circulation half-life, inefficient delivery to target sites, and TRAIL resistance have hindered clinical translation. Recent advances in drug delivery, materials science, and nanotechnology are now being exploited to develop next-generation nanoparticle platforms to overcome barriers to TRAIL therapeutic delivery. Here, we review the design and implementation of nanoparticles to enhance TRAIL-based cancer therapy. The platforms we discuss are diverse in their approaches to the delivery problem and provide valuable insight into guiding the design of future nanoparticle-based TRAIL cancer therapeutics to potentially enable future translation into the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据